Sanofi (SNY) Getting Somewhat Positive Media Coverage, Report Shows

News coverage about Sanofi (NYSE:SNY) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.8746327459059 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

SNY has been the subject of several research reports. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Morgan Stanley downgraded Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Finally, Cowen set a $48.00 price target on Sanofi and gave the stock a “hold” rating in a research note on Monday, December 18th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $49.33.

Shares of Sanofi (SNY) traded down $0.04 during mid-day trading on Thursday, reaching $39.82. 153,763 shares of the company traded hands, compared to its average volume of 2,475,708. Sanofi has a 12-month low of $38.14 and a 12-month high of $50.65. The firm has a market cap of $99,347.42, a P/E ratio of 10.87, a price-to-earnings-growth ratio of 2.06 and a beta of 0.85. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26.

Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.07). Sanofi had a net margin of 23.25% and a return on equity of 37.09%. The firm had revenue of $8.69 billion during the quarter, compared to analyst estimates of $8.65 billion. During the same period in the previous year, the firm posted $1.25 EPS. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year. sell-side analysts predict that Sanofi will post 3.37 EPS for the current year.

The business also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be paid a dividend of $1.8609 per share. The ex-dividend date of this dividend is Wednesday, May 9th. This represents a dividend yield of 4.72%. This is an increase from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is currently 30.14%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://weekherald.com/2018/02/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-sanofi-sny-share-price.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Insider Buying and Selling by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply